Copyright Reports & Markets. All rights reserved.

Global Choroidal Neovascularization Drug Market Research Report 2019

Buy now

Table of Contents

    Global Choroidal Neovascularization Drug Market Research Report 2018

      1 Choroidal Neovascularization Drug Market Overview

      • 1.1 Product Overview and Scope of Choroidal Neovascularization Drug
      • 1.2 Choroidal Neovascularization Drug Segment by Type (Product Category)
        • 1.2.1 Global Choroidal Neovascularization Drug Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
        • 1.2.2 Global Choroidal Neovascularization Drug Production Market Share by Type (Product Category) in 2017
        • 1.2.3 AVMOC-001
        • 1.2.3 BB-3
        • 1.2.5 BBT-007
        • 1.2.6 DG-3
        • 1.2.7 Entolimod
        • 1.2.8 EWA-001

      Others

      • 1.3 Global Choroidal Neovascularization Drug Segment by Application
        • 1.3.1 Choroidal Neovascularization Drug Consumption (Sales) Comparison by Application (2013-2025)
        • 1.3.2 Clinic
        • 1.3.3 Hospital
        • 1.3.4 Others
      • 1.4 Global Choroidal Neovascularization Drug Market by Region (2013-2025)
        • 1.4.1 Global Choroidal Neovascularization Drug Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
        • 1.4.2 North America Status and Prospect (2013-2025)
        • 1.4.3 Europe Status and Prospect (2013-2025)
        • 1.4.4 China Status and Prospect (2013-2025)
        • 1.4.5 Japan Status and Prospect (2013-2025)
        • 1.4.6 Southeast Asia Status and Prospect (2013-2025)
        • 1.4.7 India Status and Prospect (2013-2025)
      • 1.5 Global Market Size (Value) of Choroidal Neovascularization Drug (2013-2025)
        • 1.5.1 Global Choroidal Neovascularization Drug Revenue Status and Outlook (2013-2025)
        • 1.5.2 Global Choroidal Neovascularization Drug Capacity, Production Status and Outlook (2013-2025)

      2 Global Choroidal Neovascularization Drug Market Competition by Manufacturers

      • 2.1 Global Choroidal Neovascularization Drug Capacity, Production and Share by Manufacturers (2013-2018)
        • 2.1.1 Global Choroidal Neovascularization Drug Capacity and Share by Manufacturers (2013-2018)
        • 2.1.2 Global Choroidal Neovascularization Drug Production and Share by Manufacturers (2013-2018)
      • 2.2 Global Choroidal Neovascularization Drug Revenue and Share by Manufacturers (2013-2018)
      • 2.3 Global Choroidal Neovascularization Drug Average Price by Manufacturers (2013-2018)
      • 2.4 Manufacturers Choroidal Neovascularization Drug Manufacturing Base Distribution, Sales Area and Product Type
      • 2.5 Choroidal Neovascularization Drug Market Competitive Situation and Trends
        • 2.5.1 Choroidal Neovascularization Drug Market Concentration Rate
        • 2.5.2 Choroidal Neovascularization Drug Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Choroidal Neovascularization Drug Capacity, Production, Revenue (Value) by Region (2013-2018)

      • 3.1 Global Choroidal Neovascularization Drug Capacity and Market Share by Region (2013-2018)
      • 3.2 Global Choroidal Neovascularization Drug Production and Market Share by Region (2013-2018)
      • 3.3 Global Choroidal Neovascularization Drug Revenue (Value) and Market Share by Region (2013-2018)
      • 3.4 Global Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.5 North America Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.6 Europe Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.7 China Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.8 Japan Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.9 Southeast Asia Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
      • 3.10 India Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

      4 Global Choroidal Neovascularization Drug Supply (Production), Consumption, Export, Import by Region (2013-2018)

      • 4.1 Global Choroidal Neovascularization Drug Consumption by Region (2013-2018)
      • 4.2 North America Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)
      • 4.3 Europe Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)
      • 4.4 China Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)
      • 4.5 Japan Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)
      • 4.6 Southeast Asia Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)
      • 4.7 India Choroidal Neovascularization Drug Production, Consumption, Export, Import (2013-2018)

      5 Global Choroidal Neovascularization Drug Production, Revenue (Value), Price Trend by Type

      • 5.1 Global Choroidal Neovascularization Drug Production and Market Share by Type (2013-2018)
      • 5.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Type (2013-2018)
      • 5.3 Global Choroidal Neovascularization Drug Price by Type (2013-2018)
      • 5.4 Global Choroidal Neovascularization Drug Production Growth by Type (2013-2018)

      6 Global Choroidal Neovascularization Drug Market Analysis by Application

      • 6.1 Global Choroidal Neovascularization Drug Consumption and Market Share by Application (2013-2018)
      • 6.2 Global Choroidal Neovascularization Drug Consumption Growth Rate by Application (2013-2018)
      • 6.3 Market Drivers and Opportunities
        • 6.3.1 Potential Applications
        • 6.3.2 Emerging Markets/Countries

      7 Global Choroidal Neovascularization Drug Manufacturers Profiles/Analysis

      • 7.1 Cellphire, Inc.
        • 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.1.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.1.2.1 Product A
          • 7.1.2.2 Product B
        • 7.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.1.4 Main Business/Business Overview
      • 7.2 Chrysalis BioTherapeutics, Inc.
        • 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.2.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.2.2.1 Product A
          • 7.2.2.2 Product B
        • 7.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.2.4 Main Business/Business Overview
      • 7.3 Cleveland BioLabs, Inc.
        • 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.3.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.3.2.1 Product A
          • 7.3.2.2 Product B
        • 7.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.3.4 Main Business/Business Overview
      • 7.4 Cumberland Pharmaceuticals, Inc.
        • 7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.4.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.4.2.1 Product A
          • 7.4.2.2 Product B
        • 7.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.4.4 Main Business/Business Overview
      • 7.5 Diffusion Pharmaceuticals Inc.
        • 7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.5.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.5.2.1 Product A
          • 7.5.2.2 Product B
        • 7.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2015-2018)
        • 7.5.4 Main Business/Business Overview
      • 7.6 Eli Lilly and Company
        • 7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.6.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.6.2.1 Product A
          • 7.6.2.2 Product B
        • 7.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.6.4 Main Business/Business Overview
      • 7.7 GNI Group Ltd.
        • 7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.7.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.7.2.1 Product A
          • 7.7.2.2 Product B
        • 7.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.7.4 Main Business/Business Overview
      • 7.8 Humanetics Corporation
        • 7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.8.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.8.2.1 Product A
          • 7.8.2.2 Product B
        • 7.8.3 Humanetics Corporation Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.8.4 Main Business/Business Overview
      • 7.9 INSYS Therapeutics, Inc.
        • 7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.9.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.9.2.1 Product A
          • 7.9.2.2 Product B
        • 7.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.9.4 Main Business/Business Overview
      • 7.8 Meabco A/S
        • 7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        • 7.10.2 Choroidal Neovascularization Drug Product Category, Application and Specification
          • 7.10.2.1 Product A
          • 7.10.2.2 Product B
        • 7.10.3 Meabco A/S Choroidal Neovascularization Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
        • 7.10.4 Main Business/Business Overview
      • 7.11 Neumedicines Inc.
      • 7.12 Onconova Therapeutics, Inc.
      • 7.13 PharmaIN Corporation
      • 7.14 Pluristem Therapeutics Inc.
      • 7.15 ProCertus BioPharm Inc.
      • 7.16 RDD Pharma Ltd.
      • 7.17 RedHill Biopharma Ltd.
      • 7.18 RxBio, Inc.
      • 7.19 Soligenix, Inc.

      8 Choroidal Neovascularization Drug Manufacturing Cost Analysis

      • 8.1 Choroidal Neovascularization Drug Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
        • 8.1.4 Market Concentration Rate of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
        • 8.2.1 Raw Materials
        • 8.2.2 Labor Cost
        • 8.2.3 Manufacturing Expenses
      • 8.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug

      9 Industrial Chain, Sourcing Strategy and Downstream Buyers

      • 9.1 Choroidal Neovascularization Drug Industrial Chain Analysis
      • 9.2 Upstream Raw Materials Sourcing
      • 9.3 Raw Materials Sources of Choroidal Neovascularization Drug Major Manufacturers in 2017
      • 9.4 Downstream Buyers

      10 Marketing Strategy Analysis, Distributors/Traders

      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
        • 10.1.3 Marketing Channel Development Trend
      • 10.2 Market Positioning
        • 10.2.1 Pricing Strategy
        • 10.2.2 Brand Strategy
        • 10.2.3 Target Client
      • 10.3 Distributors/Traders List

      11 Market Effect Factors Analysis

      • 11.1 Technology Progress/Risk
        • 11.1.1 Substitutes Threat
        • 11.1.2 Technology Progress in Related Industry
      • 11.2 Consumer Needs/Customer Preference Change
      • 11.3 Economic/Political Environmental Change

      12 Global Choroidal Neovascularization Drug Market Forecast (2018-2025)

      • 12.1 Global Choroidal Neovascularization Drug Capacity, Production, Revenue Forecast (2018-2025)
        • 12.1.1 Global Choroidal Neovascularization Drug Capacity, Production and Growth Rate Forecast (2018-2025)
        • 12.1.2 Global Choroidal Neovascularization Drug Revenue and Growth Rate Forecast (2018-2025)
        • 12.1.3 Global Choroidal Neovascularization Drug Price and Trend Forecast (2018-2025)
      • 12.2 Global Choroidal Neovascularization Drug Production, Consumption , Import and Export Forecast by Region (2018-2025)
        • 12.2.1 North America Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.2 Europe Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.3 China Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.4 Japan Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.5 Southeast Asia Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
        • 12.2.6 India Choroidal Neovascularization Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
      • 12.3 Global Choroidal Neovascularization Drug Production, Revenue and Price Forecast by Type (2018-2025)
      • 12.4 Global Choroidal Neovascularization Drug Consumption Forecast by Application (2018-2025)

      13 Research Findings and Conclusion

        14 Appendix

        • 14.1 Methodology/Research Approach
          • 14.1.1 Research Programs/Design
          • 14.1.2 Market Size Estimation
          • 14.1.3 Market Breakdown and Data Triangulation
        • 14.2 Data Source
          • 14.2.1 Secondary Sources
          • 14.2.2 Primary Sources

        This report studies the global Choroidal Neovascularization Drug market status and forecast, categorizes the global Choroidal Neovascularization Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

        The major manufacturers covered in this report
        Cellphire, Inc.
        Chrysalis BioTherapeutics, Inc.
        Cleveland BioLabs, Inc.
        Cumberland Pharmaceuticals, Inc.
        Diffusion Pharmaceuticals Inc.
        Eli Lilly and Company
        GNI Group Ltd.
        Humanetics Corporation
        INSYS Therapeutics, Inc.
        Meabco A/S
        Neumedicines Inc.
        Onconova Therapeutics, Inc.
        PharmaIN Corporation
        Pluristem Therapeutics Inc.
        ProCertus BioPharm Inc.
        RDD Pharma Ltd.
        RedHill Biopharma Ltd.
        RxBio, Inc.
        Soligenix, Inc.

        Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        We can also provide the customized separate regional or country-level reports, for the following regions:
        North America
        United States
        Canada
        Mexico
        Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Rest of Asia-Pacific
        Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
        Rest of Europe
        Central & South America
        Brazil
        Argentina
        Rest of South America
        Middle East & Africa
        Saudi Arabia
        Turkey
        Rest of Middle East & Africa

        On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
        AVMOC-001
        BB-3
        BBT-007
        DG-3
        Entolimod
        EWA-001
        Others
        On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
        Clinic
        Hospital
        Others

        The study objectives of this report are:
        To analyze and study the global Choroidal Neovascularization Drug capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
        Focuses on the key Choroidal Neovascularization Drug manufacturers, to study the capacity, production, value, market share and development plans in future.
        Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
        To define, describe and forecast the market by type, application and region.
        To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
        To identify significant trends and factors driving or inhibiting the market growth.
        To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
        To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
        To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
        To strategically profile the key players and comprehensively analyze their growth strategies.

        In this study, the years considered to estimate the market size of Choroidal Neovascularization Drug are as follows:
        History Year: 2013-2017
        Base Year: 2017
        Estimated Year: 2018
        Forecast Year 2018 to 2025

        For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

        Key Stakeholders
        Choroidal Neovascularization Drug Manufacturers
        Choroidal Neovascularization Drug Distributors/Traders/Wholesalers
        Choroidal Neovascularization Drug Subcomponent Manufacturers
        Industry Association
        Downstream Vendors

        Available Customizations
        With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:
        Regional and country-level analysis of the Choroidal Neovascularization Drug market, by end-use.
        Detailed analysis and profiles of additional market players.

        Buy now